Back to today’s briefing

Story perspectives

FDA Approves Moderna's RSV Vaccine for At-Risk Adults

6/15/2025

26 3

Summary

Moderna's RSV Vaccine Approved

The FDA has given the green light to Moderna's RSV vaccine, mRESVIA, for adults aged 18-59 who face heightened risks of severe illness. This pivotal decision, rooted in Phase III trial findings, underscores the serious threat RSV poses to younger adults with chronic health issues. Expect mRESVIA to roll out in time for the 2025-2026 respiratory virus season.

Summary

Moderna's Ambitious Future

Moderna's stock has plummeted 80% in three years, driven by waning demand for COVID-19 vaccines and lackluster RSV sales. Yet, the company remains ambitious, targeting ten product approvals, including innovative cancer vaccines. Meanwhile, the Department of Health and Human Services has slashed funding for mRNA research, raising safety concerns that experts argue are baseless.

1 of 2

Moderna's RSV Vaccine Approved

The FDA has given the green light to Moderna's RSV vaccine, mRESVIA, for adults aged 18-59 who face heightened risks of severe illness. This pivotal decision, rooted in Phase III trial findings, underscores the serious threat RSV poses to younger adults with chronic health issues. Expect mRESVIA to roll out in time for the 2025-2026 respiratory virus season.

1 / 2